CNS CRO is pleased to announce that pre-clinical work, using stroke model technology now exclusively licensed to CNS CRO, had promoted the test compound NA1 directly from rodent testing to successful Phase I through IIA trials. Now a successful Phase IIB trial has been concluded by NoNO Inc. demonstrating clinical efficacy in the ENACT trial for embolic stroke…more

CNS|CRO is bolstering its animal models for neurological diseases through a licensing deal with the University of Prince Edward Island (UPEI). Continue reading at: http://www.outsourcing-pharma.com/Preclinical-Research/CNS-CRO-adds-neurological-animal-models-from-UPEI...